Darolutamide Plus ADT, Docetaxel Improves OS in Patients with mHSPC, Regardless of Disease Volume and Risk
The triplet therapy should become the new standard of care for this patient population, according to recent data.
Sactiuzumab Govitecan Significantly Improves OS in Pretreated HR+/HER2- Metastatic Breast Cancer
Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.
Radiotherapy Can Be Paired with Next-Gen Hormonal Therapy in Phase 3 HRLPC Trials
According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.
NSCLC With Baseline Brain Metastases Predictive of Limited Benefit from Mobocertinib
In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.
Ibrutinib With SOC Shows Significant PFS Improvement in Older Patients With MCL
Ibrutinib combined with bendamustine and rituximab extended the highest progression-free survival rate ever reported for this patient population, in the phase 3 SHINE study.
Distrust Among Black Patients With mBC Impacts Participation in Clinical Trials
According to a survey, some Black patients with metastatic breast cancer harbor distrust toward clinical trials, which has impacted the number of Black patients who participate.
Cabozantinib Following IO Therapy Failure Confirmed Safe, Feasible in Metastatic RCC
New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.
Superior PFS to FCR in Previously Untreated CLL Seen With Ibrutinib Plus Rituximab
While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.
Updated Results Show Continued Ibrutinib After Fixed-Duration Ibrutinib-Venetoclax Has Durable Responses in CLL
New results from the CAPTIVATE study demonstrated that treatment with ibrutinib and venetoclax in the first-line setting of patients with CLL continues to elicit durable responses to placebo.
Sabizabulin Appears Effective and Safe in Metastatic Castration Resistant Prostate Cancer
In patients with metastatic castration resistant prostate cancer, sabizabulin was well tolerated and associated with significant and durable objective tumor responses
A ‘More Active Role’ is Needed From Urologist in Reporting Smoking Assessment, Cessation in Clinical Trials
Future studies on genitourinary cancer may be limited as many currently lack data on how smoking impacts outcomes in this patient population.
Wellness Modality May Improve QoL and Immune Responses in Patients with Prostate Cancer
Phase 2 research highlights a wellness modality that may improve outcomes in men with prostate cancer.
Axi-Cel Outperforms Alternate Treatments in R/R Follicular Lymphoma
Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Selpercatinib May be an Effective NSCLC Treatment
Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.
Aumolertinib Extends PFS and Duration of Response in EGFR+ Non–Small Cell Lung Cancer
Treatment with aumolertinib led to improved progression free survival and duration of response in patients with advanced non-small cell lung caner with epidermal growth factor receptor, compared with gefitinib.
Pralsentinib Demonstrates Tolerability and Elicits Durable Responses in RET Fusion-Positive NSCLC
In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.
Nivolumab and Cabozantinib Combo Found to Improve Quality of Life for Patients with Advanced RCC
Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.
2 Clarke Drive Cranbury, NJ 08512